Pay for Delay: U.S. Says Drugmakers Block Cheaper Generic Rivals

May 5, 2011
Fox Business
By Elizabeth MacDonald

The Federal Trade Commission has found an "unprecedented" 60% jump in drug industry "pay for delay" deals that stall consumers' access to cheaper generic drugs, hurting consumers' and taxpayers' wallets.

The report could lay the groundwork for even more antitrust, anti-monopoly actions the government has increasingly been bringing against Big Pharma.

Drug companies “struck an unprecedented number of deals” in fiscal 2010, where drug makers of brand name pharmaceuticals paid “potential generic rivals and generic companies to defer the introduction of lower-cost medicines for American consumers, the FTC said in a statement. Read more

Also In The News

Tell Us Your Thoughts

How do you feel about having to pay more than everyone else for your medication? Tell us your story. **By filling out this form you are giving RxRights permission to use your comments to help build support for safe, affordable drug importation.**